Key Highlights

  • Shares were up 12.42% to USD 0.3946 in pre-market trading on November 3, 2026.
  • On November 2, 2026, the company announced arrival of a QuickStrip oral thin-film production line.
  • The company says the platform could generate up to USD 15 million in Revenue in its first 18 months of operation.
  • The projection depends on successful qualification of the equipment.
  • An October 20, 2026 release cited a USD 16 million Investment for a planned IV bag facility.

Pre-Market Gain After a Production Line Announcement (up USD 0.0436, 12.42%)

Callan JMB (NASDAQ:CJMB) was up 12.42% to USD 0.3946 in pre-market trading on November 3, 2026, measured against the November 2, 2026 close. The move follows a company press release dated November 2, 2026.

Because the stock trades below USD 1, this is a penny stock, and such shares can be volatile, thinly traded and exposed to dilution risk.

The Catalyst in Detail

According to the press release, the company received a complete QuickStrip oral thin-film production line from Rapid Dose Therapeutics for installation at its Texas facility. The company called the shipment its entry into U.S. oral thin-film production.

QuickStrip is a platform that uses rapidly dissolving strips to deliver active ingredients without water or traditional dosage forms. The company said the line is expected to support fast-dissolving products for pharmaceutical, nutraceutical and government healthcare uses.

Management said it believes the platform could generate up to USD 15 million in revenue during the first 18 months of operation. The release made that projection conditional on successful qualification of the equipment, and it did not disclose an installation timeline, qualification date, equipment cost or margins.

Business Background

Callan JMB describes itself as a diversified healthcare logistics, preparedness and critical infrastructure company based in Spring Branch, Texas. Its services include fulfillment, warehousing, cold-chain logistics, regulatory compliance and specialty packaging.

The company says it is building a broader platform that adds domestic pharmaceutical manufacturing, critical electrical infrastructure, specialty industrial Manufacturing and energy development.

In an October 20, 2026 release, the company announced approval of blueprints for an IV bag manufacturing and distribution Facility in Marion, Alabama, with projected annual revenue of USD 450 million once in production. The release cited a USD 16 million investment and gave no construction or production start date.

Risks to Consider

Both announcements are forward-looking. The company cited customer adoption, regulatory approvals, product qualification, market conditions and execution as risks, and said actual results may differ materially.

The company said its chief executive stated that neither the QuickStrip project nor the IV bag facility requires it to raise additional capital. Investors may still note that the releases do not provide cash balances or financing terms, and the company has referred readers to the risk factors in its Form S-1.

What to Watch Next

Traders will watch whether the stock holds its pre-market level once regular trading opens on November 3, 2026, and whether Volume remains elevated.

Further items to follow include installation and qualification updates for the QuickStrip line, progress on the Alabama IV bag facility, and any regulatory filings that clarify funding and share count.